XBI SPDR S&P Biotech ETF

$XBI $HELP ripe for a monstrous phase 3 drop any moment. Clear multibagger potential. Relative to competition potential for a 5x or more. DFTX at $4b with it's MDD candidate scoring a -8 on rhe MADRS scale. HELP at $650m with its adjunct MDD candidate HLP003 scoring a -13 at phase 2 that extended to a -18.5 with a second dose 6 weeks later. The phase 3 read out is any day now.

$XBI you just know the M&A melee is going to ramp up in the next days and weeks, there have been a few, but much more spending coming from the big boys soon. $RIGL $IBRX $PRLD

One thing I've learned from a history of biotech gut punches $XBI No knee jerk reactions- take my time to slowly digest. Only take action when ready 🙌

As long as $XBI $BBH don’t bahhhreak down let $SMH carve out the bahhhtom of this large consolidation. Chop chop huckleberries……. 🧠👀

$XBI turning red, expected after Congress turns blue. perhaps as others have noted, this leads to M&A. $TGTX $AUPH $OMER $MIST either way, holding my shares.

$XBI multiple taps of the trend line. Currently facing a 50-61.8 fib retracement zone. Rejection here raises the risk of a trend line breach.

$XBI thru trend-line today, next hurdle will be 50sma to get through but great start. Needs to hold 150 zone

red days are when this check actually earns its keep imo $XBI near 149.66 today, down about 5.9% off a 159.10 close, and back under its 50 day near 155.94 so a name that is green right now is not riding the sector, it's beating it that's the whole tell. up 2% on a flat day is noise, up 2% on a day like this is strength the ones I care about are the names holding green while the index bleeds everything else is just getting carried and the carry is gone today watchlist gets built on days like this, not on the green ones

Thursday closed green and quiet, which honestly suits me fine $XBI closed 157.79, up about 0.2% off 157.51 $IBB closed 217.86, up about 0.7% off 216.35 $INSM closed 111.59, up about 15.1% off 96.98, Q3 revenue 524.4 million, up 268% from a year ago, Brinsupri doing the heavy lifting $IOVA gave back about 35% to near 9.57 on updated lung data, but the 24.6% response held up in 69 patients, 43.3% in KRAS wild type, and a 2027 filing plan is still the clock imo Alnylam pulled back hard on its own print even with Q3 revenue at 1.46 billion, up 17%, and product revenue up 52% to 1.29 billion. that is a reset, not a broken story tomorrow is the one, $INO Oct 30 PDUFA for INO 3107 in RRP, inspections done and the late cycle meeting behind it

$XBI Hope folks listened as $SLS is cratering. $SLS/REGAL concerns: 1) Misled investors by presenting Pilot Study data as Phase 2 data 2) Modified the treatment arm dosing midtrial to improve outcomes 3) Misleading AML CR1 data 4) Curated/Misleading SLS009 data 5) Goal post shifts 6) REGAL assumptions failed miserably 7) Trial censoring impacts 8) allo-SCT impacts 9) Discontinued collaborations 10) Questionable financial moves 11) Poor management history with ties to bankruptcies, failed trials, and SEC/Law Firm investigations 12) Self-imposed Quiet Period after Shareholder complaints filed with the SEC 13) Law Firm Investigations 14) Communication starvation 15) Sweetened separation packages for termination (non-Change of Control) 16) Added 20 million shares for Execs (offset share value drop?) 17) Massive improvements in treatments/care benefiting BAT arm 18) Physician's Choice arm promotes individualized treatments (like $MRNA and $MRK) 19) Healthier patient population 20) ?

Thursday close and biotech just gave back the whole Wednesday rip imo $XBI closed 148.40, down 6.7% off 159.10 $IBB closed 209.99, down 5.0% off 221.13 broad risk off day, chips led the slide and biotech got swept along $XERS up 25.0% to 13.08, Q3 revenue up 44% to 107.2 million and the 2030 target raised past 1 billion $VCEL up 13.9% to 51.78, Q3 revenue up 26% and guidance lifted $CYTK down 12.7% to 55.55 even after beating the quarter, MAPLE PDUFA Nov 14 still the clock that matters tomorrow Moderna prints Q3 before the open, Cogent too, and SITC late breaking abstracts land Friday

$XBI testing underside of pivot but overall still looks like a strong setup regardless if it pulls back from here

$XBI institutions can load cheap before earning season....imo this is one of the last deep red days before reversal (just like may 5 2025)

Seeking Alpha has introduced polls!! 🙂 Look forward to doing these regularly and the value they can add (500+ biotech investors & traders in our group) $XBI Will also share on X where appropriate *Can be larger things like sector outlook, readouts for certain stocks, etc

$XBI $XLV Health Care’s Best Month Ever Against the Market As money fled technology, defensive sectors absorbed it. The Health Care Select Sector SPDR Fund is on track for its best month ever relative to the SPDR S&P 500 ETF Trust(SPY) , outperforming by 11% in October, according to data going back to 1998. The previous record was March 2020, at 9.9%. The iShares Biotechnology ETF climbed to an all-time high this week. Regeneron Pharmaceuticals Inc.(REGN) surged 11% on Friday, its best day since October 2025.

$XBI $LABD $LABU Open Interest by Strike for next weeks OPEX Puts out number Calls more than 2.5 to 1

$XBI Democrats are much better for market in the long run because they're more reasonable, don't start wars in Iran for no reason and don't take instructions from foreign governments without scrutiny, funds and analysis. Relief rally is coming after this nonsense panic settles.

Continues to be one of my favorite metrics- 6 of 10 ppl who kick the tires end up sticking around To me that means something we're doing is adding value for them $XBI Other's the 92% retention rate (actually higher as includes ppl who turned off auto-renew but aren't leaving)

$XBI considering $IWM taking a hit from unborn fomc and inflation statement, small cap bio is bucking the trend to alpha land in part thx to a accommodative fda and ai shortening cycles for all stages from preclinical to clinical through regulatory review $IBB biotech should continue to outperform many others including other area of healthcare imho

$XBI For those considering joining the $SLS P&D hype, consider these $SLS/REGAL concerns: 1) Misled investors by presenting Pilot Study data as Phase 2 data 2) Modified the treatment arm dosing midtrial to improve outcomes 3) Misleading AML CR1 data 4) Curated/Misleading SLS009 data 5) Goal post shifts 6) REGAL assumptions failed miserably 7) Trial censoring impacts 8) allo-SCT impacts 9) Discontinued collaborations 10) Questionable financial moves 11) Poor management history with ties to bankruptcies, failed trials, and SEC/Law Firm investigations 12) Self-imposed Quiet Period after Shareholder complaints filed with the SEC 13) Law Firm Investigations 14) Communication starvation 15) Sweetened separation packages for termination (non-Change of Control) 16) Added 20 million shares for Execs (offset share value drop?) 17) Massive improvements in treatments/care benefiting BAT arm 18) Physician's Choice arm promotes individualized treatments (like $MRNA and $MRK) 19) Healthier patient population 20) ?